Springer

Dear Author

Here are the proofs of your article.

- You can submit your corrections **online,** via **e-mail** or by **fax**.
- For **online** submission please insert your corrections in the online correction form. Always indicate the line number to which the correction refers.
- You can also insert your corrections in the proof PDF and **email** the annotated PDF.
- For **fax** submission, please ensure that your corrections are clearly legible. Use a fine black pen and write the correction in the margin, not too close to the edge of the page.
- Remember to note the **journal title**, **article number**, and **your name** when sending your response via e-mail or fax.
- **Check** the metadata sheet to make sure that the header information, especially author names and the corresponding affiliations are correctly shown.
- **Check** the questions that may have arisen during copy editing and insert your answers/corrections.
- **Check** that the text is complete and that all figures, tables and their legends are included. Also check the accuracy of special characters, equations, and electronic supplementary material if applicable. If necessary refer to the *Edited manuscript*.
- The publication of inaccurate data such as dosages and units can have serious consequences. Please take particular care that all such details are correct.
- Please **do not** make changes that involve only matters of style. We have generally introduced forms that follow the journal's style.
- Substantial changes in content, e.g., new results, corrected values, title and authorship are not allowed without the approval of the responsible editor. In such a case, please contact the Editorial Office and return his/her consent together with the proof.
- If we do not receive your corrections **within 48 hours**, we will send you a reminder.
- Your article will be published **Online First** approximately one week after receipt of your corrected proofs. This is the **official first publication** citable with the DOI. **Further changes are, therefore, not possible.**
- The **printed version** will follow in a forthcoming issue.

Please note

After online publication, subscribers (personal/institutional) to this journal will have access to the complete article via the DOI using the URL:
http://dx.doi.org/10.1007/s10875-016-0281-8

If you would like to know when your article has been published online, take advantage of our free alert service. For registration and further information, go to: http://www.link.springer.com.

Due to the electronic nature of the procedure, the manuscript and the original figures will only be returned to you on special request. When you return your corrections, please inform us, if you would like to have these documents returned.

AUTHOR'S PROOF

Metadata of the article that will be visualized in OnlineFirst

Please note: Images will appear in color online but will be printed in black and white.

1	Article Title	**Dominant Splice Site Mutations in *PIK3R1* Cause Hyper IgM Syndrome, Lymphadenopathy and Short Stature**	
2	Article Sub- Title		
3	Article Copyright - Year	**Springer Science+Business Media New York 2016 (This will be the copyright line in the final PDF)**	
4	Journal Name	Journal of Clinical Immunology	

5	Corresponding Author	Family Name	**Buckley**
6		Particle	
7		Given Name	**Rebecca H.**
8		Suffix	
9		Organization	Duke University Medical Center
10		Division	Department of Pediatrics, Division of Allergy and Immunology
11		Address	363 Jones Building, Box 2898, Durham 27710, NC, USA
12		Organization	Duke University Medical Center
13		Division	Department of Immunology
14		Address	Durham 27710, NC, USA
15		e-mail	buckl003@mc.duke.edu
16	Author	Family Name	**Petrovski**
17		Particle	
18		Given Name	**Slavé**
19		Suffix	
20		Organization	Columbia University
21		Division	Institute for Genomic Medicine
22		Address	New York 10032, NY, USA
23		e-mail	
24	Author	Family Name	**Parrott**
25		Particle	
26		Given Name	**Roberta E.**
27		Suffix	
28		Organization	Duke University Medical Center
29		Division	Department of Pediatrics, Division of Allergy and Immunology

30		Address	363 Jones Building, Box 2898, Durham 27710, NC, USA
31		e-mail	
32	Author	Family Name	**Roberts**
33		Particle	
34		Given Name	**Joseph L.**
35		Suffix	
36		Organization	Duke University Medical Center
37		Division	Department of Pediatrics, Division of Allergy and Immunology
38		Address	363 Jones Building, Box 2898, Durham 27710, NC, USA
39		e-mail	
40	Author	Family Name	**Huang**
41		Particle	
42		Given Name	**Hongxiang**
43		Suffix	
44		Organization	Duke University Medical Center
45		Division	Department of Pediatrics, Division of Allergy and Immunology
46		Address	363 Jones Building, Box 2898, Durham 27710, NC, USA
47		Organization	Southern Medical University
48		Division	Department of Oncology, Nanfang Hospital
49		Address	Guangzhou 510515, Guangdong, China
50		e-mail	
51	Author	Family Name	**Yang**
52		Particle	
53		Given Name	**Jialong**
54		Suffix	
55		Organization	Duke University Medical Center
56		Division	Department of Pediatrics, Division of Allergy and Immunology
57		Address	363 Jones Building, Box 2898, Durham 27710, NC, USA
58		e-mail	
59	Author	Family Name	**Gorentla**
60		Particle	
61		Given Name	**Balachandra**
62		Suffix	
63		Organization	Duke University Medical Center
64		Division	Department of Pediatrics, Division of Allergy and Immunology

Line		Field	Value
65		Address	363 Jones Building, Box 2898, Durham 27710, NC, USA
66		e-mail	
67	Author	Family Name	**Mousallem**
68		Particle	
69		Given Name	**Talal**
70		Suffix	
71		Organization	Duke University Medical Center
72		Division	Department of Pediatrics, Division of Allergy and Immunology
73		Address	363 Jones Building, Box 2898, Durham 27710, NC, USA
74		Organization	Wake Forest University School of Medicine
75		Division	Departments of Internal Medicine and Pediatrics
76		Address	Winston-Salem, NC, USA
77		e-mail	
78	Author	Family Name	**Wang**
79		Particle	
80		Given Name	**Endi**
81		Suffix	
82		Organization	Duke University Medical Center
83		Division	Department of Pathology
84		Address	Durham 27710, NC, USA
85		e-mail	
86	Author	Family Name	**Armstrong**
87		Particle	
88		Given Name	**Martin**
89		Suffix	
90		Organization	UCB NewMedicines
91		Division	
92		Address	Slough, UK
93		e-mail	
94	Author	Family Name	**McHale**
95		Particle	
96		Given Name	**Duncan**
97		Suffix	
98		Organization	UCB NewMedicines
99		Division	
100		Address	Slough, UK
101		e-mail	

AUTHOR'S PROOF

102		Family Name	**MacIver**
103		Particle	
104		Given Name	**Nancie J.**
105		Suffix	
106		Organization	Duke University Medical Center
107	Author	Division	Department of Pediatrics, Division of Endocrinology
108		Address	Durham 27710, NC, USA
109		Organization	Duke University Medical Center
110		Division	Department of Immunology
111		Address	Durham 27710, NC, USA
112		e-mail	
113		Family Name	**Goldstein**
114		Particle	
115		Given Name	**David B.**
116	Author	Suffix	
117		Organization	Columbia University
118		Division	Institute for Genomic Medicine
119		Address	New York 10032, NY, USA
120		e-mail	
121		Family Name	**Zhong**
122		Particle	
123		Given Name	**Xiao-Ping**
124		Suffix	
125		Organization	Duke University Medical Center
126	Author	Division	Department of Pediatrics, Division of Allergy and Immunology
127		Address	363 Jones Building, Box 2898, Durham 27710, NC, USA
128		Organization	Duke University Medical Center
129		Division	Department of Immunology
130		Address	Durham 27710, NC, USA
131		e-mail	

132		Received	12 February 2016
133	Schedule	Revised	
134		Accepted	31 March 2016

135 Abstract

The purpose of this research was to use next generation sequencing to identify mutations in patients with primary immunodeficiency diseases whose pathogenic gene mutations had not been identified. Remarkably, four unrelated patients were found by next generation sequencing to have the same heterozygous mutation in an essential donor splice site of *PIK3R1* (NM_181523.2:c.1425 + 1G > A) found in three prior reports. All four had the

Hyper IgM syndrome, lymphadenopathy and short stature, and one also had SHORT syndrome. They were investigated with in vitro immune studies, RT-PCR, and immunoblotting studies of the mutation's effect on mTOR pathway signaling. All patients had very low percentages of memory B cells and class-switched memory B cells and reduced numbers of naïve CD4+ and CD8+ T cells. RT-PCR confirmed the presence of both an abnormal 273 base-pair (bp) size and a normal 399 bp size band in the patient and only the normal band was present in the parents. Following anti-CD40 stimulation, patient's EBV-B cells displayed higher levels of S6 phosphorylation (mTOR complex 1 dependent event), Akt phosphorylation at serine 473 (mTOR complex 2 dependent event), and Akt phosphorylation at threonine 308 (PI3K/PDK1 dependent event) than controls, suggesting elevated mTOR signaling downstream of CD40. These observations suggest that amino acids 435–474 in PIK3R1 are important for its stability and also its ability to restrain PI3K activity. Deletion of Exon 11 leads to constitutive activation of PI3K signaling. This is the first report of this mutation and immunologic abnormalities in SHORT syndrome.

136	Keywords separated by ' - '	PIK3R1 splice site mutations - Hyper IgM syndrome - lymphadenopathy - short stature - SHORT syndrome - mTOR pathway - next generation sequencing
137	Foot note information	The online version of this article (doi:10.1007/s10875-016-0281-6) contains supplementary material, which is available to authorized users.

Electronic supplementary material

ESM 1

Figure S1**:** Sanger sequencing traces of DNA sequence around the *PIK3R1* donor splice site for each patient (1–4) and their parents (M = Mother, F = Father). Both forward (+) and reverse (−) directions are provided. Patients are heterozygous for the variant. The variant was not observed in the unaffected parents. Father of Patient 4 was unavailable. (JPEG 2560 kb)

J Clin Immunol
DOI 10.1007/s10875-016-0281-6

ORIGINAL ARTICLE

Dominant Splice Site Mutations in *PIK3R1* Cause Hyper IgM Syndrome, Lymphadenopathy and Short Stature

Slavé Petrovski[1] · Roberta E. Parrott[2] · Joseph L. Roberts[2] · Hongxiang Huang[2,3] · Jialong Yang[2] · Balachandra Gorentla[2] · Talal Mousallem[2,4] · Endi Wang[5] · Martin Armstrong[6] · Duncan McHale[6] · Nancie J. MacIver[7,8] · David B. Goldstein[1] · Xiao-Ping Zhong[2,8] · Rebecca H. Buckley[2,8]

Received: 12 February 2016 / Accepted: 31 March 2016
© Springer Science+Business Media New York 2016

Abstract The purpose of this research was to use next generation sequencing to identify mutations in patients with primary immunodeficiency diseases whose pathogenic gene mutations had not been identified. Remarkably, four unrelated patients were found by next generation sequencing to have the same heterozygous mutation in an essential donor splice site of *PIK3R1* (NM_181523.2:c.1425 + 1G > A) found in three prior reports. All four had the Hyper IgM syndrome, lymphadenopathy and short stature, and one also had SHORT syndrome. They were investigated with in vitro immune studies, RT-PCR, and immunoblotting studies of the mutation's effect on mTOR pathway signaling. All patients had very low percentages of memory B cells and class-switched memory B cells and reduced numbers of naïve CD4+ and CD8+ T cells. RT-PCR confirmed the presence of both an abnormal 273 base-pair (bp) size and a normal 399 bp size band in the patient and only the normal band was present in the parents. Following anti-CD40 stimulation, patient's EBV-B cells displayed higher levels of S6 phosphorylation (mTOR complex 1 dependent event), Akt phosphorylation at serine 473 (mTOR complex 2 dependent event), and Akt phosphorylation at threonine 308 (PI3K/PDK1 dependent event) than controls, suggesting elevated mTOR signaling downstream of CD40. These observations suggest that amino acids 435–474 in PIK3R1 are important for its stability and also its ability to restrain PI3K activity. Deletion of Exon 11 leads to constitutive activation of PI3K signaling. This is the first report of this mutation and immunologic abnormalities in SHORT syndrome.

Electronic supplementary material The online version of this article (doi:10.1007/s10875-016-0281-6) contains supplementary material, which is available to authorized users.

✉ Rebecca H. Buckley
buckl003@mc.duke.edu

Q1 [1] Institute for Genomic Medicine, Columbia University, New York, NY 10032, USA

Q2 [2] Department of Pediatrics, Division of Allergy and Immunology, Duke University Medical Center, 363 Jones Building, Box 2898, Durham, NC 27710, USA

[3] Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China

[4] Departments of Internal Medicine and Pediatrics, Wake Forest University School of Medicine, Winston-Salem, NC, USA

[5] Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA

[6] UCB NewMedicines, Slough, UK

[7] Department of Pediatrics, Division of Endocrinology, Duke University Medical Center, Durham, NC 27710, USA

[8] Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA

Keywords PIK3R1 splice site mutations · Hyper IgM syndrome · lymphadenopathy · short stature · SHORT syndrome · mTOR pathway · next generation sequencing

Introduction

Many critical aspects of immune cell development, differentiation and function are controlled by phosphoinositdtide 3 kinases (PI3Ks) [1]. Information is accruing about the effects of human gene mutations affecting these molecules. Hyperactivation of the PI3K signaling pathway due to heterozygous gain-of-function mutations in the gene encoding PIK3CD has been found by several groups to result in defects in immune function [2–5]. The resulting clinical problems included respiratory infections, Epstein Barr virus and/or cytomegalovirus infections, antibody deficiency, lymphadenopathy and lymphoma

UNCORRECTED PROOF

AUTHOR'S PROOF

susceptibility. More recently, dominant mutations in the gene encoding PIK3R1, the p85α regulatory subunit for PIK3CD, were also found to result in constitutive hyperactivation of that pathway and immunodeficiency [6–8]. Currently, the dominant *PIK3R1* mutations linked to constitutive hyperactivation have been restricted to mutations of essential donor splice sites in intron 11, resulting in the exclusion of exon 11 ($p85\alpha^{\Delta 434_475}$) [6, 7, 9]. Prior to these reports, a homozygous loss-of-function genotype in exon 6 of *PIK3R1* was reported in a female patient characterized by agammaglobulinemia and absent B cells [10]. In addition, other dominant *de novo* mutations in exon 14 of *PIK3R1* have been described among patients with SHORT syndrome characterized by short stature, hyperextensibility of joints, delayed bone age, hernias, low body mass index and a progeroid appearance [11–16]. No results of immune studies were recorded in the SHORT syndrome patients in the existing reports.

The purpose of this research was to use next generation sequencing to identify mutations in patients with primary immunodeficiency diseases whose pathogenic gene mutations had not been identified. Four unrelated patients were found by next generation sequencing to have the same *de novo* heterozygous mutation in an essential donor splice site of *PIK3R1* (NM_181523.2:c.1425 + 1G > A) found in three prior reports [6–8]. All four had the Hyper IgM syndrome, lymphadenopathy and short stature, and one also had a clinical diagnosis of SHORT syndrome.

Patient, Materials and Methods

Patients

The patients from four unrelated families were referred to the Immunology Clinic at Duke University Medical Center (DUMC). All studies were performed with the approval of the DUMC Institutional Review Board and with the written informed consent of the patients' parents.

Patient 1 A 2.5 year old Caucasian male born to nonconsanguineous healthy parents began having recurrent otitis, sinusitis and dacryocystitis in early infancy. He also had problems with intermittent hypoglycemia. On examination, he was found to be symmetrically small with height and weight below the 5th percentile. He had enlarged tonsils and large cervical, axillary and inguinal lymph nodes. Family history was negative for immunodeficiency. On immune evaluation, he was found to have an IgG of 78, an IgA of 0, an IgM of 155 and an IgE of <1 and was started on monthly intravenous immunoglobulin infusions (Table 1). He is currently alive but with recurrent respiratory infections and lymphadenopathy.

Patient 2 A 2.4 year old Caucasian female was born to nonconsanguineous healthy parents and was healthy until she began having recurrent otitis and pneumonia at 2.3 years of age. On examination, she was found to be symmetrically small with height and weight below the 10th percentile. She had large tonsils and massive cervical adenopathy and an elevated serum IgM of 209 mg/dl with very low levels of all of the other immunoglobulins (Table 1). She was started on monthly intravenous immunoglobulin infusions and is currently alive but with continued lymphadenopathy.

Patient 3 A 6 year old Caucasian male was born to nonconsanguineous healthy parents and began having recurrent otitis and dacryocystitis in infancy, followed by pneumonia on three occasions at age 4 years. On examination he was found to be symmetrically small, with height and weight below the 5th percentiles. Patient 3's height was less than the fifth percentile for all visits; his mean parental height would predict that he should be at the 25th percentile for height as an adult. He had large tonsils, enlarged cervical, axillary and inguinal lymph nodes and splenomegaly. Immune evaluation at age 4 years revealed that he had undetectable serum IgA, IgG and IgE but an IgM of 529 mg/dl (Table 1). He is currently alive and receiving monthly IVIG with splenic peliosis but is otherwise well.

Patient 4 A 5 year old Caucasian female was born to nonconsanguineous healthy parents and began having recurrent pneumonias at age 3 years. She also had numerous bouts of otitis and had two sets of tympanostomy tubes. She has congenital dacryostenosis. She had large tonsils and adenoids and they were removed. Immune evaluation at age 5 years revealed undetectable serum IgA and IgE, an IgG of 68 mg/dl and an IgM of 197 mg/dl (Table 1). At age 12, she was diagnosed independently by the Genetics Division as having SHORT syndrome after ruling out multiple other genetic causes of short stature through whole exome sequencing in a commercial laboratory where the only abnormality detected was the *PIK3R1*mutation. Patient 4's height was at the 0.01 percentile for all visits and her mean parental height would predict that she should be at the 25th percentile as an adult. She has a triangular facial shape with a prominent forehead, deep set eyes, thin nostrils, a low-hanging columella, a downturned small mouth, a small chin, a conductive hearing loss, hyperextensibility of the joints, delayed eruption of the secondary teeth, lack of subcutaneous fat and a learning disability. She is currently alive and receiving monthly IVIG.

Immunologic Phenotype Analysis

Flow cytometry of peripheral blood leucocytes was performed with labeled Abs to CD3ε, CD4, CD8, CD10, CD14, CD16, CD20, CD22, CD24, CD25, CD27, CD38, CD45, CD45RA, CD45RO, CD56, CD57, IgD, IgM, CD62L, CD197, CD279,

UNCORRECTED PROOF

Q5/Q4

Table 1

Patient	1	2	3	4	
Gender	Male	Female	Male	Female	
Age at Presentation (yr)	1 7/12	2 5/12	2	5 1/2	
Growth Percentile	**<5th**	**<10th**	**5th**	**<<<5th**	
Viral Infections	–	–	RSV, H1N1 Parainfluenza	–	
Lymphoproliferation	**3+**	**3+**	**3+**	**2+**	
Autoimmunity	–	–	–	–	
Allergy	–	–	–	–	
Respiratory Infections	Ear, Sinus	Throat, Lung	Eye, Ear, Lung	Eye, Ear, Lung	
Other Features	–	–	–	Abnormal facies[a]	
Ig Replacement	+	+	+		**Normal Ranges**
IgG[b] mg/dl (Age in yr)	**78** (1 7/12)	**47** (2 5/12)	**<60** (4 1/12)	**68** (5 ½)	391–1047
IgA[b] mg/dl (Age in yr)	**6** (1 7/12)	**8** (2 5/12)	**<16** (4 1/12)	0 (5 ½)	15–95
IgM[b] mg/dl (Age in yr)	**155** (1 7/12)	**209** (2 5/12)	**529** (4 1/12)	**197** (5 ½)	49–202
IgE[b] I.U./ml (Age in yr)	**<10** (1 7/12)	**8** (2 5/12)	**<10** (4 1/12)	**1** (5 ½)	0–150
Lymphocyte Studies (Yr)	13 1/4	10 3/4	10 1/3	13 1/12	
Absolute Lymphocyte Ct	1280	1476	**770**	1254	1000–4800
CD3+ T cells/μl	891	1231	708	1157	631–4142
CD3+ CD4 + T cells/μl	**321**	344	**324**	658	340–2746
CD3+ CD8 + T cells/μl	392	773	181	433	154–1776
Naïve[c] CD4 + T cells (%)	**14.2**	**31.1**	**11.1**	**14.2**	[i]35.6–72.5
Naïve[d] CD8 + T cells (%)	**14.2**	**5.4**	41.2	39.4	[i]36.1–74.2
[e]CD3 + CD8 + PD-1+/μl	56	**325**	20	22	12–141
CD19+ B cells/μl	182	**38**	**16**	**29**	51–821
[f]Transitional B cells (%)	**52.7 % (102 abs)**	4.02 % **(0 abs)**	**48.8 % (5 abs)**	14.2 % **(4 abs)**	[j]2.9 %–23.8 % (12–35 abs)
[g]Memory B cells (%)	3.3 % (6 abs)	11.9 % **(1 abs)**	4.4 % **(0 abs)**	**1.2 % (0 abs)**	1.4–27.6 % (4-168abs)
[h]Switched Memory B (%)	8.5 % (16 abs)	11.9 % **(1 abs)**	3.7 % **(0 abs)**	**2.4 % (1 abs)**	3.0–32.9 % (13-105abs)
CD3-CD56+ NK cells/μl	175	155	16	36	12–864
PHA Stimulated Cells (cpm)	**64,853** (1483)	144,073 (2812)	**115,456** (981)	137,276 (1914)	117,512–235,792
Anti-CD3 Stimulated (cpm)	**53,366** (1483)	133,166 (2812)	**33,415** (981)	**27,782** (1528)	59,808–186,006
Candida Stimulated (cpm)	**1415** (888)	41,566 (1450)	**6149** (4076)	**495** (545)	6460–60,028

Abnormal values are in bold font

[a] Triangular shape, deep-set eyes, thin nostrils, low-hanging columella, downturned small mouth, small chin and prominent forehead

[b] Normal ranges for immunoglobulins are for 2 year old Caucasians

[c] Naïve CD4+ T cells are CCR7 + CD45RA+/CD4+/CD3+

[d] Naïve CD8+ T cells are CCR7 + CD45RA+/CD8+/CD3+

[e] Senescent CD8+ T cells are CD57 + (PD-1)+/CD8+/CD3+

[f] Transitional B cells are CD24++CD38++/IgD + CD27−/CD19+

[g] Unswitched memory B cells are IgD + CD27+/CD19+

[h] Class switched memory B cells are CD27 + IgD−/CD19+

[i] Reference range provided by Dr. Alan Kirk of Department of Surgery, Duke University Medical Center

[j] Reference range from R. van Gent et al.: Clin. Immunol. 133: 95–107, 2009

UNCORRECTED PROOF

TCRαβ, and TCRγδ. Samples were collected on a BD FACSCanto II cytometer and data analyzed using FACSDiva software. Lymphocyte proliferation was assessed by measuring $[^3H]$thymidine incorporation into mononuclear cells following culture with optimal concentrations of the indicated stimuli as previously described [17].

Next Generation Sequencing, Alignment and Variant Calling

Next generation sequencing was carried out on the HiSeq2000 within the Genomic Analysis Facility in the Center for Human Genome Variation (Duke University). DNA samples from

AUTHOR'S PROOF JrnlID 10875_ArtID 281_Proof# 1 - 06/04/2016

164 Patients 1 and 2 were analyzed using whole exome sequencing and from Patient 3 by whole genome sequencing. For the exome sequenced samples, sequencing libraries were prepared from primary DNA extracted from leukocytes of patients using either the KAPA Biosystem's (patient 1) or Illumina TruSeq (patient 2) library preparation kit following the manufacturer's protocol. For patient 1 and his parents, the Nimblegen SeqCap EZ V3.0 Enrichment kit (Roche NimbleGen, Madison, WI) was used to selectively amplify the coding regions of the genome according to the manufacturer's protocol. For patient 2, the 65-Mb Illumina TruSeq Exome Enrichment Kit (Illumina, San Diego, CA) was used to selectively amplify the coding regions of the genome according to the manufacturer's protocol. Patient 3 was whole-genome sequenced. Whole exome sequencing was performed initially at a commercial CLIA-certified laboratory for patient 4, and the mutation was confirmed by the authors.

181 Alignment of the sequenced DNA fragments to the Human Reference Genome (NCBI Build 37) was performed using the Burrows–Wheeler Alignment Tool (BWA) (version 0.5.10). The reference sequence used is identical to the 1000 Genomes Phase II reference and it consists of chromosomes 1–22, X, Y, MT, unplaced and unlocalized contigs, the human herpesvirus 4 type 1 (NC_007605), and decoy sequences (hs37d5) derived from HuRef, Human Bac and Fosmid clones and NA12878.

189 After alignments were produced for each individual separately using BWA, variant and genotype calling was performed using the Genome Analysis Tool Kit (GATK, version 1.6–11-g3b2fab9). SnpEff (version 3.3) was used to annotate the variants according to Ensembl (version 73) and consensus coding sequencing (CCDS release 14) and limited analyses to protein-coding or essential splice site (2 base pairs flanking an exon) mutations.

197 The sequence data for patients 1–3 were analyzed using established protocols that identify qualifying variants forming genotypes not observed in an in-house control database of 2357 samples or 60,706 sequenced samples made available by the Exome Aggregation Consortium (ExAC), Cambridge, MA (URL: http://exac.broadinstitute.org (accessed Jan., 2015, release 0.3). The *PIK3R1* essential splice site *de novo* mutations were independently validated with Sanger sequencing for each trio.

206 Establishment of EBV Cell Lines and Cell Growth

207 Cyclosporine A, B95.8 culture EBV supernatant, and media (RPMI 1640 + PenStrep + L-glu + Hepes + 20%FBS) were added to 10 million peripheral blood leucocytes [18]. EBV-immortalized B-cell lines from patients and controls were cultured in RPMI 1640 medium (Sigma-Aldrich) supplemented with 20 % FBS (HyClone), 100 U/mL penicillin G, 100 U/mL streptomycin, 292 μg/mL of L-glutamine and 10 mM HEPES (N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid; pH 7.4). To determine cell expansion, 2×10^4 of EBV-transformed B-cell lines were plated in a 96-well plate in 0.2 mL media. Cell numbers were counted after cultured for 24, 48 and 72 h.

219 Immunoblot Analysis

220 EBV-transformed B cells were rested in PBS for 30′ at 37 °C followed by stimulation with an anti-CD40 antibody for 10 or 30 min or with human insulin (Sigma-Aldrich) for the indicated times and subsequently lysed in 1 % Nonidet P-40 lysis buffer containing freshly added protease and phosphatase inhibitor cocktails. Cell lysates were subjected to immunoblotting analysis using anti-p85α, phosphor-S6, S6 protein, phosphor-Akt serine 473, and β-actin antibodies according to published protocols [19].

229 RT-PCR and DNA Sequencing

230 Total RNAs from PBMCs lysed in the Trizol reagent were isolated according to the manufacturer's protocol. The first strand cDNA was made using the iScript Select cDNA Synthesis Kit (Bio-Rad). PIK3R1 cDNA was amplified using primers huPIK3R1F 5'-TGGGAAATATGGCTTCTCTGA-3 and huPIK3R1R 5'-TCTTTCTCATTGCCTTCACG-3' aligning to exon 10 and 12, respectively. PCR products were separated and visualized by agarose gel electrophoresis and further sequenced to identify aberrant splicing.

239 Glucose Uptake

240 To measure glucose uptake, cells were washed and resuspended in Krebs-Ringer-HEPES (at pH 7.4, 136 mM NaCl, 4.7 ml KCl, 1.25 mM $CaCl_2$, 1.25 mM $MgSO_4$, and 10 mM HEPES). 2-Deoxy-D-H^3 glucose (2 μCi/reaction) was added, and the cells were incubated for 10 min at 37 °C. The reactions were quenched by the addition of ice-cold 200 μM phloretin (Calbiochem, Gibbstown, NJ) followed by centrifugation through an oil layer (1:1 Dow Corning 550 Silicon fluid from Motion Industries, Birmingham, AL; and dinonyl phthalate from Sigma-Aldrich). The cell pellets were washed and solubilized in 1 M NaOH, and radioactivity was measured using a scintillation counter.

252 Results

253 **Patients** All four patients have had recurrent upper and/or lower respiratory infections from early childhood, but only one had a history of viral infections and only with viral agents that cause upper respiratory illnesses (Table 1). They have not had recurrent fungal infections nor have they had opportunistic infections. Three have had recurrent bacterial

UNCORRECTED PROOF

dacryocystitis, and one has had intermittent hypoglycemia. All four are symmetrically small: three had heights and weights below the 5th percentile and patient 2's height was below the 10th percentile. Three of the patients have had peripheral lymphadenopathy and the fourth had very large tonsils and adenoids that were removed. The lymph nodes are generally very large and are often soft and movable. Three patients have had lymph nodes excised and no lymph node has been found to be malignant. Lymph node histology in the three for whom it is available revealed hyperplastic lymphoid follicles with attenuated mantle zones (Fig. 1). Only one has splenomegaly and that is complicated by peliosis. None of the patients has autoimmunity or allergy. Only one patient is lymphopenic. Two of them have low numbers of B cells, and all have very low percentages of memory B cells and class-switched memory B cells. One of them has an elevated percentage and number of transitional B cells. They all have normal numbers of natural killer cells, although one has only 16 such cells. Their T cell counts are all within the normal range, but two of them have inverted CD4:CD8 ratios. All of them have low percentages of naïve CD4+ T cells, and two have low percentages of naïve CD8+ T cells. One of the patients has elevated CD8 senescent T cells (Table 1). T cell functional studies in the four patients suggest some T cell impairment in that two had low responses to PHA, three had low responses to immobilized anti-CD3 and three had no response to candida (Table 1).



Fig. 1 Histopathology of cervical lymph node biopsy of Patient 1. **a** A low magnification demonstrates reactive follicular hyperplasia with expanded germinal centers and attenuated mantle zones, as indicated by the *arrows*. Note the polarity of well-defined germinal centers. H&E stain, ×40. **b** Immunohistochemical stain for CD20 highlights well defined germinal centers with diminished mantle zones or absence of mantle zones, as indicated by the *arrows*. Note an apparently naked germinal center without mantle zone in *upper left*, as indicated by the *arrowhead*, and increased B-cells in the interfollicular area. Anti-CD20 stain, ×40

Mutation Whole exome sequencing of patient 1 and his parents identified a putative *de novo* mutation in an essential donor splice site of *PIK3R1* (NM_181523.2:c.1425 + 1G > A) (Supplementary Fig. 1). Among our set of 50 patients who have undergone next generation sequencing for immunodeficiency of unknown molecular type, we identified three other patients, patients 2, 3 and 4, with the exact same *de novo* *PIK3R1* essential donor splice site mutation (NM_181523.2:c.1425 + 1G > A) (Supplementary Fig. 1). Variation at this essential splice site was not observed among 2357 samples sequenced for various projects at the Institute for Genomic Medicine, Columbia University (formerly the Center for Human Genome Variation, Duke University); nor was it observed among 59,413 samples among the ExAC consortia dataset that had at least 10-fold coverage at this precise site. For patients 1–3, the parents were also Sanger sequenced for the mutation and it was confirmed that the mutation arose *de novo* in those patients. For patient 4, who was clinically whole exome sequenced initially by a commercial CLIA-certified laboratory, the variant was Sanger confirmed in the child and confirmed to be absent in mother, but her father was unavailable (Supplementary Fig. 1). It is likely these *de novo* mutations arose in the germline cells; however, we have not ruled out the possibility that the mutations may be post-zygotic—limited to the hematopoietic system. In our patient population, we have not yet observed instances of the other two described *PIK3R1* essential splice variants at the same site: NM_181523.2:c.1425 + 1G > C or NM_181523.2:c.1425 + 1G > T [6, 7].

Detection of Aberrant Splicing of Mutant mRNA

To determine if the mutation results in skipping of exon 11, we amplified *PIK3R1* cDNA from total RNAs from patient 1 and his parents PBMCs using primers corresponding to exon 10 and 12 of the gene (transcript NM_181523.2). Both parents generated a single normal 399 base-pair (bp) band. The patient sample, however, produced both a 399 bp band and a unique 273 bp band (Fig. 2). Further sequencing of the PCR products

UNCORRECTED PROOF

AUTHOR'S PROOF



Fig. 2 **a**–**c** Aberrant splicing in *PIK3R1* mRNA in patient 1. **a** Detection of mutant form of *PI3K1R* mRNA by RT-PCR. **b** Sequence of normal and mutant allele cDNA. **c** Chromatographs showing aberrant exon 10 to 12 splicing in patient 1's mutant *PIK3R1* allele. **d** Detection of p85α protein in lysates from EBV-immortalized B cells from patient 1 and his parents. In the patient sample, the intensity of the band corresponding to p85α is decreased and there is a weak band (*blue arrow*) that could be vaguely see right beneath the p85α band, which is likely the exon 11 deletion mutant of p85α. The band indicated with a *red arrow* is only seen in patient, which is likely a degraded product of the mutant p85α. The identities of the other two bands indicated by *, whether they are non-specific proteins detected by the anti-p85α antibody or degradation products of p85α, are unknown at present. **e** Assessment of S6 and Akt phosphorylation in EBV-B cells following anti-CD40 stimulation. EBV-B cells from patient 1 and her parents were rested in PBS at 37oC for 30' and then stimulated with an anti-CD40 antibody (10 μg/ml) for 10 or 30 min. Cell lysates were subjected to immunoblotting analysis with the indicated antibodies

revealed that the 273 bp band was produced by direct exon 10 to 12 splicing.

Effects of $p85\alpha^{\Delta434_475}$ Mutation on Signaling

To examine how $p85\alpha^{\Delta434_475}$ mutation might affect p85α, we generated EBV-immortalized B cell lines from patient 1 and his parents. As shown in Fig. 2d, patient EBV-B cells expressed lower level of p85α compared with parent control. In addition, a small protein band of about 30 kDa was only observed in the patient's B cells but not parents. Thus, the mutant protein might be less stable than the WT protein. An important downstream event of PIK3 signaling is the activation of mTOR. Activated mTOR phosphorylates and activates S6 K1, leading to subsequent phosphorylation of the ribosomal protein S6. After resting in PBS at 37 °C for 30 min, EVB-B cells from both parents of patient 1 did not contain obvious S6 phosphorylation (mTOR complex 1 dependent event), Akt phosphorylation at serine 473 (mTOR complex 2 dependent event), and Akt phosphorylation at threonine 308 (PI3K/PDK1 dependent event). However, a low level but noticeable phosphorylation of these molecules was observed in patient 1's EBV-B cells, suggesting constitutive activation of PI3K-mTOR signaling (Fig. 2e). Following anti-CD40 stimulation, patient 1's EBV-B cells displayed a higher level of S6 and Akt phosphorylation than controls, suggesting elevated PI3K/PDK1 and mTOR signaling downstream of CD40. The same was true when they were stimulated with insulin for both patient 1 (top panel, Fig. 3a) and patient 4 (bottom panel, Fig. 3a). Moreover, patient EBV-B cells had increased uptake of ^{3}H-2-deoxy-glucose following 1 h of stimulation with insulin, and were more responsive to insulin than the parent/control EBV-B cells (Fig. 3b). Altogether, these observations suggest that amino acids 435–474 in PIK3R1 are important for its stability and also restrain PI3K activity. Its deletion may lead to constitutive activation of PI3K/Akt/mTOR signaling, which is consistent with recent reports of patients with similar mutations [6–8].

Discussion

Including the 12 patients in the three earlier reports [6–8] all sixteen known cases of *PIK3R1* immunodeficiency have had mutations at this essential donor splice site (NM_181523.2:c.1425 + 1G > A/C/T). Despite this apparent limited allelic heterogeneity for *PIK3R1* immunodeficiency, the findings in the four patients presented here continue to highlight the heterogeneity of the clinical and immunologic abnormalities of the patients who have $p85\alpha^{\Delta434_475}$ *PIK3R1* essential splice mutations [6–8]. The clinical features of the four patients reported here are uniform and similar to some but not all of those described by Deau et al. [6] and Lucas et al. [7]. This could possibly be due to the younger ages of our patients when compared with those of Lucas et al. [7], but the ages at presentation of our patients were similar to three of the four patients described by Deau et al. [6] and all of the patients reported by Lougaris et al. [8] All four of our patients had short stature; poor growth was noted in the patients reported by Lucas et al. [7] and Lougaris et al. [8] but in only one of those reported by Deau et al. [6] Lymphadenopathy and/or tonsillar hypertrophy were noted in all four of our patients and in the four reported by Lucas et al. [7], and in three of the four reported by Lougaris et al. [8] but in only one of those reported by Deau et al. [6] None of our patients has had a diagnosed malignancy as yet and none has had problems with CMV or EBV. Our patients were each diagnosed clinically as having the Hyper IgM syndrome, but none of them had any of the known gene mutations reported in the Hyper IgM syndrome. Patient 1 had been found to have a common CD40L polymorphism, but his CD4+ T cells displayed functional CD40L after activation [20]. Patient 4, with her diagnosis of SHORT syndrome, appears to be a unique case compared to other patients with this same mutation. While there may exist another mutation in Patient 4 that makes the presentation unique, it was not found in chromosomal microarray studies, fragile X studies, whole exome sequence analysis in the commercial lab setting, subsequent Sanger sequencing of *PIK3R1* exon 14, or in deletion testing of the mitochondrial genome.

PIK3R1 is an established pleiotropic gene. In addition to immunodeficiency, SHORT syndrome has been reported to be caused by dominant *de novo* mutations in exon 14 of *PIK3R1* [11–16]. Immunologic studies were not reported on in those earlier SHORT syndrome publications. Thus, our Patient 4 with SHORT syndrome having the same mutation at this essential donor splice site (NM_181523.2:c.1425 + 1G > A/C/T) in intron 11 as well as the same immunologic findings as the other patients with *PIK3R1* immunodeficiency, provides an important link within *PIK3R1* mediated disease. The commercial lab reported Patient 4 as negative for additional *PIK3R1*, or other SHORT syndrome disease gene, variants. We also subsequently Sanger sequenced *PIK3R1* exon 14 in our research lab setting and confirmed that both Patient 4 and her mother were not carriers of variants in exon 14. We performed glucose uptake studies because some but not all patients with SHORT syndrome have been insulin resistant. However, in keeping with the fact than none of the four patients reported here were clinically insulin resistant, the glucose uptake studies were normal (Fig. 3).

Our data suggest that $p85\alpha^{\Delta434\text{–}475}$ *PIK3R1* mutations lead to elevated PI3K activity. The immunodeficiency observed in our patients is similar to those with gain-of-function mutations in *PIK3CD*, suggesting that this *PIK3R1* mutation might cause elevated PIK3CD activity [21]. At present, it is still

UNCORRECTED PROOF

AUTHOR'S PROOF



Fig. 3 **a** Assessment of S6 phosphorylation in EBV-B cells following anti-CD40 stimulation. EBV-B cells from patients 1 and 4 and their mothers were rested in PBS at 37 °C for 30' and then either unstimulated or stimulated with insulin (1 μM) for the indicated minutes. Cell lysates were subjected to immunoblotting analysis with the indicated antibodies. **b** Assessment of glucose uptake before and after insulin stimulation: EBV-transformed B cells from Patients1, 2 and 4 their parents (controls) were rested in PBS for 30 min followed by culture in the presence or absence of 1–2 μM insulin for 30–60 min. Glucose uptake was determined

UNCORRECTED PROOF

425 unclear how the p85α$^{\Delta 434_475}$ mutation causes increased PI3K activity. Normal p85α stabilizes the p110 catalytic subunit but inhibits its lipid kinase activity in unstimulated cells. Under stimulating conditions, p85α recruits p110 to activated receptors or adaptor molecules via its SH2 domain, leading to activation of its kinase activity [22, 23]. Because the inter-SH2 domain of p85α is involved in p85α - p110 heterodimerization [24], it is possible that the p85α$^{\Delta 434_475}$ mutant inefficiently inhibits its cognate partner p110 (p110δ in the hematopoietic cells and p110α in muscle and other tissues), leading to elevated PI3K signaling. Additionally, p85α$^{\Delta 434_475}$ was underpresented compared with WT p85α in patients' samples, indicating that amino acids absent in the mutant in the inter-SH2 domain are important for its stability. 438

439 The concomitant observation of SHORT syndrome in patient 4 is interesting in that it confirms *PIK3R1* as a hot spot of mutation for this syndrome. It also suggests that the p85α$^{\Delta 434_475}$ mutation may affect other catalytic PI3K subunits such as PIK3CA that are known to be important for insulin receptor signaling [25]. It is important to note that some SHORT syndrome patients with mutations in exon 14 [11–14] and a murine model mimicking one of the *PIK3R1* mutations [26] displayed impaired PI3K signaling. Studies have demonstrated that chronic overactivation of signal pathways can lead impairment of receptor induced signaling [27]. It is possible that chronic overactivation of the PI3K pathway might trigger a negative feedback mechanism(s) that prevents normal insulin receptor signaling in some tissues, although we did not find abnormal signaling in patient 4's blood lymphocytes. 454

455 The immunologic abnormalities in our patients were similar in many but not all respects to those previously reported [6–8]. Three of our patients have low numbers of B cells, and all have very low percentages of memory B cells and class-switched memory B cells. IgM was elevated in all four of our patients, in three of the four patients reported by Deau et al. [6], all of the patients reported by Lougaris et al. [8] but in only one of the patients reported by Lucas et al. [7] Most of our patients have low percentages of naïve CD4+ and CD8+ T cells, but only one had elevated CD8 senescent T cells as reported by Lucas et al. [7] T cell functional studies in our patients suggest some T cell impairment but this was not commented on in the three prior reports [6–8]. T cell dysfunction would not be unexpected, since PI3K signaling is required for the differentiation of T cells into subsets [1]. 469

470 *PIK3R1* has been identified as a gene intolerant to functional variation in the general human population. The Residual Variation Intolerance Score (RVIS) for *PIK3R1* is −0.76, which corresponds to a ranking of 13.5 % most intolerant genes, genome wide (http://igm.cumc.columbia.edu/GenicIntolerance/). The intolerance of a gene to functional variation among the human population has been demonstrated to be highly predictive of disease-causing genes, particularly those causing disease through a dominant model [28]. Existing mouse knock-out work has also shown that disruptions to *Pik3r1* result in a wide range of B cell 480

phenotypes [29]. Moreover, *Pik3r1* is considered an 'essential' gene, with mouse knock-outs resulting in complete perinatal lethality and partial postnatal lethality [29]. We have previously shown that the bioinformatics signature of a disruptive *de novo* mutation in an intolerant gene that is also known to be essential is highly linked to pathogenicity among children with undiagnosed genetic disorders [30].

Available mTOR inhibitors as well as non-selective PI3K inhibitors approved for use in other conditions already exist. A range of next generation PI3K inhibitors, which are highly selective for the delta isoform, are under development. These drugs could offer a pharmacological solution for these patients where existing treatment options are very limited and include extreme therapies such as bone marrow transplantation. The availability of highly selective orally available PI3Kdelta inhibitors has the potential to normalize the pathological mechanism in these patients.

Conclusions

Together, these observations suggest that amino acids 435–474 in PIK3R1 are important for its stability and also its ability to restrain PI3K activity. Deletion of exon 11 leads to constitutive activation of PI3K signaling. The clinical and immunologic manifestations of patients with dominant splice site mutations in *PIK3R1* have been variable, with all having very low percentages of memory B cells and class-switched memory B cells and reduced percentages of naïve CD4+ and CD8+ T cells. The clinical manifestations in our patients were uniform, with all having the Hyper IgM syndrome, short stature and lymphadenopathy, except that one also had a clinical diagnosis of SHORT syndrome. This is the first report of immunologic abnormalities and this precise mutation in a patient ascertained for SHORT syndrome. The elucidation of the molecular mechanism in these patients results in the opportunity for new and potentially transformative therapeutic options.

Acknowledgments This study was supported by the following grants: Baxter Healthcare Grant BT13-21694 to R.H.B. and NIH Grant R01 AI101206 to X-P. Z. Partial funding for this study was provided by UCB Celltech, including salary support for D.B.G. M.A. and D.M. are employees of UCB. The other authors declare no conflict of interest. S.P. is a National Health and Medical Research Council (NHMRC) CJ Martin Fellow. We thank our patients and their parents for participating in this study. We also thank B Krueger, J Bridges, Q Wang, N Ren, S Gewalt, S Kisselev, Y-F Lu, K Cronin, and N Walley for excellent technical support. We would like to acknowledge the following individuals for the contributions of control samples: W. B. Gallentine, E.L. Heinzen, A.M. Husain, K. N. Linney, M. A. Mikati, R. A. Radtke, and S. R. Sinha; J.P. McEvoy, A. Need, J. Silver, and *M. Silver*; D. H. Murdock and The MURDOCK Study Community Registry and Biorepository; G. Cavalleri, N. Delanty, and C. Depondt; J. Burke, C. Hulette, and K. Welsh-Bohmer; J. Milner; J. Hoover-Fong, N. L. Sobreira and D. Valle; E. J. Holtzman; W. L. Lowe; P. Lugar; S. M. Palmer; Z. Farfel, D. Lancet, E. Elon Pras; A. Poduri; M. Hauser; D. Marchuk; D. Koltai Attix, O. Chiba-Falek; E. T. Cirulli, V. Dixon and J. McEvoy; K. Schmader, S. McDonald, H. K. White, M. Yanamadala, and the Carol Woods and Croasdale Retirement Communities; R. Gbadegesin and M. Winn; D. Daskalakis; Q. Zhao; A. Holden and E. Behr; R. Brown; and S. Kerns and H. Oster. The collection of control samples was funded in part by Bryan ADRC NIA P30 AG028377, the Ellison Medical Foundation New Scholar award AG-NS-0441-08, an award from SAIC-Frederick, Inc. (M11-074), funding from Biogen Idec, NIMH awards RC2MH089915, R01MH097971, R01MH099216, and K01MH098126, the Epi4K Gene Discovery in Epilepsy study (NINDS U01-NS077303) and the Epilepsy Genome/Phenome Project (EPGP - NINDS U01-NS053998), and the Center for HIV/AIDS Vaccine Immunology ("CHAVI") under a grant from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (UO1AIO67854), NIAID (R01AI079088 and R01AI101206). Finally, the authors would also like to thank the Exome Aggregation Consortium and the groups that provided exome variant data for comparison. A full list of contributing groups can be found at http://exac.broadinstitute.org/about.

References

1. Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol. 2013;31:675–704.
2. Angulo I, Vadas O, Garcon F, Banham-Hall E, Plagnol V, Leahy TR, et al. Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage. Science. 2013;342(6160):866–71.
3. Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. Nat Immunol. 2014;15(1):88–97.
4. Kracker S, Curtis J, Ibrahim MA, Sediva A, Salisbury J, Campr V, et al. Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase delta syndrome. J Allergy Clin Immunol. 2014;134(1):233–6.
5. Crank MC, Grossman JK, Moir S, Pittaluga S, Buckner CM, Kardava L, et al. Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility. J Clin Immunol. 2014;34(3):272–6.
6. Deau MC, Heurtier L, Frange P, Suarez F, Bole-Feysot C, Nitschke P, et al. A human immunodeficiency caused by mutations in the PIK3R1 gene. J Clin Invest. 2014;124(9):3923–8.
7. Lucas CL, Zhang Y, Venida A, Wang Y, Hughes J, McElwee J, et al. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K. J Exp Med. 2014;211(13):2537–47.
8. Lougaris V, Faletra F, Lanzi G, Vozzi D, Marcuzzi A, Valencic E, et al. Altered germinal center reaction and abnormal B cell peripheral maturation in PI3KR1-mutated patients presenting with HIGM-like phenotype. Clin Immunol. 2015;159(1):33–6.
9. Deau MC, Heurtier L, Frange P, Suarez F, Bole-Feysot C, Nitschke P, et al. A human immunodeficiency caused by mutations in the PIK3R1 gene. J Clin Invest. 2015;125(4):1764–5.
10. Conley ME, Dobbs AK, Quintana AM, Bosompem A, Wang YD, Coustan-Smith E, et al. Agammaglobulinemia and absent B lineage cells in a patient lacking the p85alpha subunit of PI3K. J Exp Med. 2012;209(3):463–70.
11. Dyment DA, Smith AC, Alcantara D, Schwartzentruber JA, Basel-Vanagaite L, Curry CJ, et al. Mutations in PIK3R1 cause SHORT syndrome. Am J Hum Genet. 2013;93(1):158–66.
12. Chudasama KK, Winnay J, Johansson S, Claudi T, Konig R, Haldorsen I, et al. SHORT syndrome with partial lipodystrophy

UNCORRECTED PROOF

AUTHOR'S PROOF JrnlID 10875_ArtID 281_Proof# 1 - 06/04/2016

595 due to impaired phosphatidylinositol 3 kinase signaling. Am J Hum
596 Genet. 2013;93(1):150–7.
597 13. Thauvin-Robinet C, Auclair M, Duplomb L, Caron-Debarle M,
598 Avila M, St-Onge J, et al. PIK3R1 mutations cause syndromic
599 insulin resistance with lipoatrophy. Am J Hum Genet. 2013;93(1):
600 141–9.
601 14. Schroeder C, Riess A, Bonin M, Bauer P, Riess O, Dobler-
602 Neumann M, et al. PIK3R1 mutations in SHORT syndrome. Clin
603 Genet. 2014;86(3):292–4.
604 15. Barcena C, Quesada V, De Sandre-Giovannoli A, Puente DA,
605 Fernandez-Toral J, Sigaudy S, et al. Exome sequencing identifies
606 a novel mutation in PIK3R1 as the cause of SHORT syndrome.
607 BMC Med Genet. 2014;15:51.
608 16. Chung BK, Gibson WT. Autosomal dominant PIK3R1 mutations
609 cause SHORT syndrome. Clin Genet. 2014;85(3):228–9.
610 17. Buckley RH, Schiff SE, Sampson HA, Schiff RI, Markert ML,
611 Knutsen AP, et al. Development of immunity in human severe
612 primary T cell deficiency following haploidentical bone marrow
613 stem cell transplantation. J Immunol. 1986;136:2398–407.
614 18. Sugden B, Mark W. Clonal transformation of adult human leuko-
615 cytes by Epstein-Barr virus. J Virol. 1977;23(3):503–8.
616 19. Gorentla BK, Wan CK, Zhong XP. Negative regulation of mTOR
617 activation by diacylglycerol kinases. Blood. 2011;117(15):4022–
618 31.
619 20. Seyama K, Nonoyama S, Gangsaas I, Hollenbaugh D, Pabst HF,
620 Aruffo A, et al. Mutations of the CD40 ligand gene and its effect on
621 CD40 ligand expression in patients with X-linked hyper IgM syn-
622 drome. Blood. 1998;92(7):2421–34.
623 21. Elgizouli M, Lowe DM, Speckmann C, Schubert D, Hulsdunker J,
624 Eskandarian Z, et al. Activating PI3Kdelta mutations in a cohort of
625 669 patients with primary immunodeficiency. Clin Exp Immunol.
626 2015;6.
627 22. Burke JE, Williams RL. Synergy in activating class I PI3Ks. Trends
628 Biochem Sci. 2015;40(2):88–100.
629 23. Geering B, Cutillas PR, Vanhaesebroeck B. Regulation of class IA
630 PI3Ks: is there a role for monomeric PI3K subunits? Biochem Soc
631 Trans. 2007;35(Pt 2):199–203.
632 24. Chiu YH, Lee JY, Cantley LC. BRD7, a tumor suppressor, interacts
633 with p85alpha and regulates PI3K activity. Mol Cell. 2014;54(1):
634 193–202.
635 25. Cheng Z, Tseng Y, White MF. Insulin signaling meets mitochondria
636 in metabolism. Trends Endocrinol Metab. 2010;21(10):589–98.
637 26. Winnay JN, Solheim MH, Dirice E, Sakaguchi M, Noh HL, Kang
638 HJ, et al. PI3-kinase mutation linked to insulin and growth factor
639 resistance in vivo. J Clin Invest. 2016. doi:10.1172/JCI84005.
640 27. Yang J, Zhang P, Krishna S, Wang J, Lin X, Huang H, et al.
641 Unexpected positive control of NFkappaB and miR-155 by
642 DGKalpha and zeta ensures effector and memory CD8+ T Cell
643 differentiation. Oncotarget. 2016. doi:10.18632/oncotarget.8164.
644 28. Petrovski S, Wang Q, Heinzen EL, Allen AS, Goldstein DB. Genic
645 intolerance to functional variation and the interpretation of personal
646 genomes. PLoS Genet. 2013;9(8):e1003709.
647 29. Blake JA, Bult CJ, Eppig JT, Kadin JA, Richardson JE. The mouse
648 genome database: integration of and access to knowledge about the
649 laboratory mouse. Nucleic Acids Res. 2014;42(Database issue):
650 D810–7.
651 30. Zhu X, Petrovski S, Xie P, Ruzzo EK, Lu YF, McSweeney KM,
652 et al. Whole-exome sequencing in undiagnosed genetic diseases:
653 interpreting 119 trios. Genet Med. 2015;17:774–81. Q6
654

UNCORRECTED PROOF

AUTHOR'S PROOF

AUTHOR QUERIES

AUTHOR PLEASE ANSWER ALL QUERIES.

Q1. Please check if the affiliations are presented correctly.
Q2. Please check captured corresponding affiliation if correct.
Q3. Please check if the section headings are assigned to appropriate levels.
Q4. Please check table entries, notes and other relevant details for table 1 if captured and presented correctly.
Q5. Please provide descriptive legend (caption) for Table 1.
Q6. Please advise if the provided volume and page numbers are correct.

UNCORRECTED PROOF